Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2957 in X-linked Myotubular Myopathy
NCT07052929Phase 2Recruiting
- Sponsor
- Astellas Gene Therapies
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
A Phase 2 trial of ASP2957 in X-linked myotubular myopathy (XLMTM), sponsored by Astellas Gene Therapies. Started Dec 2025; status: recruiting.
02
Drugs
ASP2957
03
Conditions
X-linked myotubular myopathy (XLMTM)
Beyond the preview
Go deeper on NCT07052929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052929.